The March edition of the Pharmaceutical CrossRoads TM
report focuses on Russia/Ukraine, covering both commercial exposure and the implications for clinical trials. Topics:
The industry’s exposure to Russia and Eastern Europe
Commercial risks in Russia and globally
Potential action on the part of Russian authorities and Pharmaceutical companies
